Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia

2009; Taylor & Francis; Volume: 24; Issue: 3 Linguagem: Inglês

10.1080/14756360802334800

1475-6374

Camilla F. C. G. de Andrade, Ricardo Bigni, Maria S. Pombo‐de‐Oliveira, Gilda Alves, Denise de Abreu Pereira,

Protease and Inhibitor Mechanisms

CD26/DPPIV (dipeptidil peptidase IV) displays an array of diverse functional properties, with a role in the development of several human cancers. This enzyme is found mainly anchored in the membrane of cells although it also has an enzymatically active plasma isoform. The regulation of biological activities of cytokines by DPP IV activity has a potential role in the homeostatic regulation of hematopoiesis. In this study, we analyzed the CD26 antigen cell membrane expression by flow cytometry and the DPPIV activity in plasma of patients of acute leukemia. The results showed that the plasma DPPIV activity is significantly higher in leukemia patients and could be 100% inhibited by Januvia (Merck Sharp & Dohme) a selective DPPIV inhibitor. Although CD26 expression on immune cells were not leukemia-dependent the analysis of the correlation between CD26 expression and the DPPIV plasma activity were statistically significant (p < 0.01) in acute lymphoid leukemia (B-ALL and T-ALL).